Dermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology Conference
October 13 2016 - 07:30AM
Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated
to identifying, developing and commercializing innovative,
differentiated therapies to improve the lives of patients with
dermatologic diseases, today announced that data from its DRM01 and
DRM04 clinical programs will be presented at the 35th Anniversary
Fall Clinical Dermatology Conference being held in Las Vegas Oct.
20 – 23, 2016.
Updated data regarding dose efficacy from the Phase 2b trial
evaluating DRM01 as a potential option for patients with acne
vulgaris will be presented. The results from two Phase 3 clinical
trials evaluating DRM04 as a potential treatment for patients with
primary axillary hyperhidrosis (excessive underarm sweating) will
also be highlighted during the meeting.
“Fall Clinical is an important meeting that allows leading
dermatology practitioners the opportunity to discuss the latest
advancements in the specialty,” said Eugene A. Bauer, M.D., chief
medical officer of Dermira and a dermatologist. “We are pleased to
have an opportunity to provide this community with an update on the
progress of Dermira’s two late-stage clinical development
programs.”
Presentations of Interest:
Title: DRM01 for the treatment of acne
vulgaris: Primary results from the DRM01-ACN02 Phase 2b randomized
controlled trialDate and Time: Available for the
duration of the meetingPresenter: Jim Del Rosso,
D.O., an adjunct clinical professor of dermatology at Touro
University College of Osteopathic MedicineSession:
General Session
Title: DRM04 for the treatment of axillary
hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3
randomized controlled trialsDate and Time:
Available for the duration of the
meetingPresenter: David Pariser, M.D., professor
at Eastern Virginia Medical School’s Department of
DermatologySession: General Session
About DermiraDermira is a biopharmaceutical
company dedicated to identifying, developing and commercializing
innovative, differentiated therapies to improve the lives of
patients with dermatologic diseases. Dermira’s portfolio includes
three late-stage product candidates that target significant unmet
needs and market opportunities: CIMZIA® (certolizumab pegol), in
Phase 3 development in collaboration with UCB Pharma S.A. for the
treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in
Phase 3 development for the treatment of primary axillary
hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b
development for the treatment of facial acne vulgaris. Dermira is
headquartered in Menlo Park, California. For more information,
please visit www.dermira.com.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com) and LinkedIn
page (https://www.linkedin.com/company/dermira-inc-) as channels of
distribution of information about its company, product candidates,
planned financial and other announcements, attendance at upcoming
investor and industry conferences and other matters. Such
information may be deemed material information and Dermira may use
these channels to comply with its disclosure obligations under
Regulation FD. Therefore, investors should monitor Dermira’s
website and LinkedIn page in addition to following its SEC filings,
press releases, public conference calls and webcasts.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements and
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, which are subject to the “safe harbor” created
by those sections. This press release contains forward-looking
statements that involve substantial risks and uncertainties,
including statements with respect to the potential use of DRM01 as
a treatment option for patients with acne vulgaris and the
potential use of DRM04 as a treatment option for patients with
primary axillary hyperhidrosis. These statements deal with future
events and involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Factors that could
cause actual results to differ materially include risks and
uncertainties such as those relating to the design, implementation
and outcome of Dermira’s clinical trials; Dermira’s dependence on
third-party clinical research organizations, manufacturers and
suppliers; Dermira’s ability to obtain regulatory approval for its
product candidates; and Dermira’s ability to continue to stay in
compliance with applicable laws and regulations. You should refer
to the section entitled “Risk Factors” set forth in Dermira’s
Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form
10-Q and other filings Dermira makes with the SEC
from time to time for a discussion of important factors that may
cause actual results to differ materially from those expressed or
implied by Dermira’s forward-looking statements. Furthermore, such
forward-looking statements speak only as of the date of this press
release. Dermira undertakes no obligation to publicly update any
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise, except as required by law.
Contacts:
Media:
Erica Jefferson
Senior Director, Head of Corporate Communications
650-421-7216
erica.jefferson@dermira.com
Investors:
Andrew Guggenhime
Chief Operating Officer and Chief Financial Officer
650-421-7200
investors@dermira.com
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
robert.uhl@westwicke.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Mar 2023 to Mar 2024